For laboratory research use only.
Cagrilintide is a long-acting amylin-analog peptide developed for metabolic research and pharmaceutical programs that target amylin-family receptors. It belongs with calcitonin-receptor / receptor-activity-modifying protein (RAMP) pharmacology—not with GHRH/GHRP secretagogues or melanocortin pigmentation ligands.
Amylin biology in brief
Amylin (islet amyloid polypeptide) is co-secreted with insulin from pancreatic β-cells and contributes to satiety and post-prandial glucose regulation in physiological descriptions. Native amylin’s therapeutic development was historically limited by physicochemical issues; long-acting analogs such as cagrilintide were designed to probe the pathway with more workable kinetics. Recent reviews of new amylin-based agonists place cagrilintide in an expanding class of agents explored for obesity and type 2 diabetes research programs (amylin-based agonists review).
What contemporary clinical-development literature shows
Much of the recent public literature discusses cagrilintide in combination regimens (notably with incretin-pathway agents under investigational names in cardiometabolic outcome and weight-management programs). Meta-analytic and trial-design papers summarize weight-loss and energy-intake outcomes for those combination programs (CagriSema weight-loss meta-analysis; continued CagriSema treatment study). Those data attach to specific investigational combinations and trial populations. They are useful for understanding why amylin analogs attract research attention; they are not instructions for laboratory catalog materials and they are not a license to import branded combination marketing into a research-identity article.
Receptor-level framing
Amylin receptors are complexes of the calcitonin receptor with RAMPs. High-level mechanism language should stay at that receptor-family level unless a protocol cites subtype-resolved papers. Cagrilintide should be searched and cited as an amylin-analog, not filed under generic “metabolic peptide” bins that also contain mitochondrial peptides or carnitine reagents.
Limits
It does not provide personal-use guidance, and it does not expand into unrelated banned product names.
Sources
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus. (Diabetes Ther, 2026, PMID 42803913)
- Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials. (Naunyn Schmiedebergs Arch Pharmacol, 2026, PMID 42608559)
- Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats. (Mol Metab, 2026, PMID 42951207)